NICE | The National Institute for Health and Care Excellence

Companies are applying for marketing authorisations for more than 10, and sometimes up to 20, therapeutic indications, where in the past it would have been exceptional to receive more than 5. This applies to cancer drugs in particular and can already be clearly seen by the amount of guidance that is either published or in development for immune ... ................
................